Form 4: Day One Biopharmaceuticals COO Charles York II Reports Stock Transactions

Charles York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., reports the acquisition and disposal of common stock and restricted stock units to cover tax liabilities.

Summary

• On February 15, 2025, Charles York II acquired common stock through the vesting of Restricted Stock Units (RSUs).
• Specifically, 1,375, 2,250, 6,625 and 6,625 shares were acquired through RSU settlements.
• On February 18, 2025, York disposed of 4,370 shares of common stock at a weighted average price of $11.963 per share.
• These sales were to cover the reporting person's tax liability with respect to the settlement of RSUs.
• Following these transactions, York directly owns 252,638 shares of Day One Biopharmaceuticals, Inc.
• York also holds derivative securities in the form of RSUs, with varying amounts vesting quarterly.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates the COO's transactions in the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the sales are primarily for tax purposes and are unlikely to significantly affect the company's performance.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, DAWN, Day One Biopharmaceuticals, Charles York II